Our identification of the importance of SOX9-TCF interactions as a driving force for Wnt target gene activation in CRC may allow the development of novel therapeutics for CRC that disrupt the TCF-SOX9 interaction. This evidence concerns the gene SOX9 and colorectal carcinoma.